Zacks Research upgraded shares of InnovAge (NASDAQ:INNV – Free Report) from a hold rating to a strong-buy rating in a research report sent to investors on Monday,Zacks reports.
A number of other equities research analysts also recently weighed in on INNV. Wall Street Zen upgraded InnovAge from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Weiss Ratings raised InnovAge from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, November 4th. Finally, KeyCorp lifted their price target on InnovAge from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.50.
Read Our Latest Analysis on InnovAge
InnovAge Stock Down 5.4%
InnovAge (NASDAQ:INNV – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. The business had revenue of $264.76 million during the quarter, compared to the consensus estimate of $257.23 million. InnovAge had a return on equity of 3.63% and a net margin of 0.88%. Analysts predict that InnovAge will post 0.44 EPS for the current year.
Insiders Place Their Bets
In other news, major shareholder Aggregator Lp Ignite sold 10,000,000 shares of the stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $9.25, for a total transaction of $92,500,000.00. Following the completion of the sale, the insider owned 102,576,555 shares in the company, valued at approximately $948,833,133.75. This represents a 8.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Carson Anderson & Stow Welsh sold 1,500,000 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $9.25, for a total value of $13,875,000.00. Following the sale, the insider directly owned 101,076,555 shares of the company’s stock, valued at approximately $934,958,133.75. This represents a 1.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 13,027,216 shares of company stock worth $120,489,535. 1.10% of the stock is owned by insiders.
Institutional Investors Weigh In On InnovAge
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of InnovAge during the second quarter valued at $17,652,000. Goldman Sachs Group Inc. increased its stake in InnovAge by 207.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 668,219 shares of the company’s stock worth $5,880,000 after purchasing an additional 450,610 shares in the last quarter. Algert Global LLC increased its stake in InnovAge by 844.1% in the 2nd quarter. Algert Global LLC now owns 630,520 shares of the company’s stock worth $7,472,000 after purchasing an additional 563,735 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in InnovAge during the 1st quarter worth about $3,349,000. Finally, Marshall Wace LLP acquired a new stake in InnovAge during the 3rd quarter worth about $3,589,000. 12.26% of the stock is owned by institutional investors and hedge funds.
About InnovAge
InnovAge, Inc. provides integrated healthcare and social services to older adults through the Program of All-Inclusive Care for the Elderly (PACE). The program serves people who qualify for nursing-home-level care but can continue living in their communities with coordinated support. InnovAge’s services include primary and specialty care coordination, nursing, rehabilitation, social services, prescription medications, transportation, in-home assistance and adult day health services. Care is coordinated by interdisciplinary teams and delivered through a combination of community-based centers and support at home.
Featured Articles
- Five stocks we like better than InnovAge
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for InnovAge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnovAge and related companies with MarketBeat.com's FREE daily email newsletter.
